KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Revenue (2016 - 2025)

Historic Revenue for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $179.5 million.

  • Pacira BioSciences' Revenue rose 649.15% to $179.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.8 million, marking a year-over-year increase of 314.18%. This contributed to the annual value of $701.0 million for FY2024, which is 385.02% up from last year.
  • Pacira BioSciences' Revenue amounted to $179.5 million in Q3 2025, which was up 649.15% from $181.1 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Revenue peaked at $187.3 million during Q4 2024, and registered a low of $119.0 million during Q1 2021.
  • Moreover, its 5-year median value for Revenue was $168.6 million (2024), whereas its average is $163.9 million.
  • In the last 5 years, Pacira BioSciences' Revenue surged by 7957.75% in 2021 and then crashed by 211.39% in 2023.
  • Quarter analysis of 5 years shows Pacira BioSciences' Revenue stood at $159.2 million in 2021, then rose by 8.02% to $172.0 million in 2022, then increased by 5.4% to $181.2 million in 2023, then grew by 3.32% to $187.3 million in 2024, then fell by 4.13% to $179.5 million in 2025.
  • Its last three reported values are $179.5 million in Q3 2025, $181.1 million for Q2 2025, and $168.9 million during Q1 2025.